The landscape of cancer treatment has changed dramatically in the last seven years, beginning with the approval of Ipilmumab in 2011, the first immunotherapy drug. Efforts to unsheathe the tumour cells of their protective microenvironment and expose them to an active immune response have delivered several monoclonal antibodies (mAbs) that…
List view / Grid view
Filter the results
Licensing agreement will expand Oxford Genetics growing bio-therapeutic discovery, design and development service business.